Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493574 | 0.91 | TP53 (0.41) | THRBMAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1612000 | 0.91 | HTT (0.45) | THRBMAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1612925 | 0.87 | SMN1; SMN2 (0.47) | THRBMAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1493469 | 0.86 | MAPT (0.44) | THRBMAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1493570 | 0.85 | TP53 (0.38) | THRBMAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1493414 | 0.85 | HSD11B1 (0.45) | THRBMAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1493310 | 0.84 | ALDH1A1 (0.42) | THRBMAPTALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1611787 | 0.84 | ALDH1A1 (0.54) | ALDH1A1HTTLMNAMAPK1 | |
| SCHEMBL1493380 | 0.82 | MAPT (0.45) | THRBMAPTALDH1A1HTTTP53 | |
| SCHEMBL1612937 | 0.80 | ALDH1A1 (0.51) | MAPTALDH1A1HTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | claimed |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | THRB 125/4885MAPT 1288/4885ALDH1A1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.